Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE) Stock Competitors & Peer Comparison
See (XENE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XENE | $55.51 | -0.49% | 4.3B | -11.70 | -$4.70 | N/A |
| VRTX | $452.93 | +4.08% | 113.8B | 26.62 | $16.84 | N/A |
| REGN | $720.88 | +1.14% | 74.5B | 17.66 | $40.96 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $792.39 | -2.57% | 50.3B | 36.06 | $22.54 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $292.21 | +2.59% | 39B | 73.19 | $3.99 | N/A |
| RVMD | $148.73 | +3.18% | 31B | -20.50 | -$7.11 | N/A |
| INSM | $118.04 | +13.62% | 25.1B | -20.14 | -$5.76 | N/A |
| UTHR | $575.74 | +1.03% | 24.7B | 21.50 | $27.06 | N/A |
Stock Comparison
XENE vs VRTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, VRTX has a market cap of 113.8B. Regarding current trading prices, XENE is priced at $55.51, while VRTX trades at $452.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas VRTX's P/E ratio is 26.62. In terms of profitability, XENE's ROE is -0.49%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, XENE is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check VRTX's competition here
XENE vs REGN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, REGN has a market cap of 74.5B. Regarding current trading prices, XENE is priced at $55.51, while REGN trades at $720.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas REGN's P/E ratio is 17.66. In terms of profitability, XENE's ROE is -0.49%, compared to REGN's ROE of +0.14%. Regarding short-term risk, XENE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check REGN's competition here
XENE vs VRNA Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, XENE is priced at $55.51, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas VRNA's P/E ratio is -102.80. In terms of profitability, XENE's ROE is -0.49%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, XENE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check VRNA's competition here
XENE vs ARGX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ARGX has a market cap of 50.3B. Regarding current trading prices, XENE is priced at $55.51, while ARGX trades at $792.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ARGX's P/E ratio is 36.06. In terms of profitability, XENE's ROE is -0.49%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, XENE is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ARGX's competition here
XENE vs SGEN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, XENE is priced at $55.51, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas SGEN's P/E ratio is -57.19. In terms of profitability, XENE's ROE is -0.49%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, XENE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check SGEN's competition here
XENE vs ALNY Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ALNY has a market cap of 39B. Regarding current trading prices, XENE is priced at $55.51, while ALNY trades at $292.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ALNY's P/E ratio is 73.19. In terms of profitability, XENE's ROE is -0.49%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, XENE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ALNY's competition here
XENE vs RVMD Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, RVMD has a market cap of 31B. Regarding current trading prices, XENE is priced at $55.51, while RVMD trades at $148.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas RVMD's P/E ratio is -20.50. In terms of profitability, XENE's ROE is -0.49%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, XENE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check RVMD's competition here
XENE vs INSM Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, XENE is priced at $55.51, while INSM trades at $118.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas INSM's P/E ratio is -20.14. In terms of profitability, XENE's ROE is -0.49%, compared to INSM's ROE of -1.30%. Regarding short-term risk, XENE is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check INSM's competition here
XENE vs UTHR Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, UTHR has a market cap of 24.7B. Regarding current trading prices, XENE is priced at $55.51, while UTHR trades at $575.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas UTHR's P/E ratio is 21.50. In terms of profitability, XENE's ROE is -0.49%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, XENE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check UTHR's competition here
XENE vs BNTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, BNTX has a market cap of 23.7B. Regarding current trading prices, XENE is priced at $55.51, while BNTX trades at $92.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas BNTX's P/E ratio is -15.69. In terms of profitability, XENE's ROE is -0.49%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, XENE is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check BNTX's competition here
XENE vs RPRX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, RPRX has a market cap of 22.2B. Regarding current trading prices, XENE is priced at $55.51, while RPRX trades at $52.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas RPRX's P/E ratio is 27.21. In terms of profitability, XENE's ROE is -0.49%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, XENE is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check RPRX's competition here
XENE vs MRNA Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, MRNA has a market cap of 21.1B. Regarding current trading prices, XENE is priced at $55.51, while MRNA trades at $50.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas MRNA's P/E ratio is -6.54. In terms of profitability, XENE's ROE is -0.49%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, XENE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check MRNA's competition here
XENE vs ROIV Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ROIV has a market cap of 21B. Regarding current trading prices, XENE is priced at $55.51, while ROIV trades at $29.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ROIV's P/E ratio is -25.12. In terms of profitability, XENE's ROE is -0.49%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, XENE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check ROIV's competition here
XENE vs BGNE Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, XENE is priced at $55.51, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas BGNE's P/E ratio is -22.55. In terms of profitability, XENE's ROE is -0.49%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, XENE is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check BGNE's competition here
XENE vs INCY Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, INCY has a market cap of 19.8B. Regarding current trading prices, XENE is priced at $55.51, while INCY trades at $98.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas INCY's P/E ratio is 14.00. In terms of profitability, XENE's ROE is -0.49%, compared to INCY's ROE of +0.29%. Regarding short-term risk, XENE is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check INCY's competition here
XENE vs DNA-WT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, XENE is priced at $55.51, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, XENE's ROE is -0.49%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, XENE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check DNA-WT's competition here
XENE vs GMAB Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, GMAB has a market cap of 16.6B. Regarding current trading prices, XENE is priced at $55.51, while GMAB trades at $26.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas GMAB's P/E ratio is 20.68. In terms of profitability, XENE's ROE is -0.49%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, XENE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check GMAB's competition here
XENE vs SMMT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, XENE is priced at $55.51, while SMMT trades at $18.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas SMMT's P/E ratio is -11.92. In terms of profitability, XENE's ROE is -0.49%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, XENE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check SMMT's competition here
XENE vs ASND Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, XENE is priced at $55.51, while ASND trades at $243.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ASND's P/E ratio is 26.61. In terms of profitability, XENE's ROE is -0.49%, compared to ASND's ROE of -56.42%. Regarding short-term risk, XENE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ASND's competition here
XENE vs JAZZ Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, JAZZ has a market cap of 14.3B. Regarding current trading prices, XENE is priced at $55.51, while JAZZ trades at $231.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas JAZZ's P/E ratio is 2071.27. In terms of profitability, XENE's ROE is -0.49%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, XENE is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check JAZZ's competition here
XENE vs BBIO Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, XENE is priced at $55.51, while BBIO trades at $69.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas BBIO's P/E ratio is -17.63. In terms of profitability, XENE's ROE is -0.49%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, XENE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check BBIO's competition here
XENE vs KRTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, XENE is priced at $55.51, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas KRTX's P/E ratio is -28.09. In terms of profitability, XENE's ROE is -0.49%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, XENE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check KRTX's competition here
XENE vs IONS Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, XENE is priced at $55.51, while IONS trades at $77.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas IONS's P/E ratio is -37.73. In terms of profitability, XENE's ROE is -0.49%, compared to IONS's ROE of -0.59%. Regarding short-term risk, XENE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check IONS's competition here
XENE vs EXEL Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, EXEL has a market cap of 12.4B. Regarding current trading prices, XENE is priced at $55.51, while EXEL trades at $51.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas EXEL's P/E ratio is 16.38. In terms of profitability, XENE's ROE is -0.49%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, XENE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check EXEL's competition here
XENE vs MDGL Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, XENE is priced at $55.51, while MDGL trades at $517.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas MDGL's P/E ratio is -37.88. In terms of profitability, XENE's ROE is -0.49%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, XENE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check MDGL's competition here
XENE vs AXSM Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, AXSM has a market cap of 11.5B. Regarding current trading prices, XENE is priced at $55.51, while AXSM trades at $234.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas AXSM's P/E ratio is -60.22. In terms of profitability, XENE's ROE is -0.49%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, XENE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check AXSM's competition here
XENE vs RNAM Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, XENE is priced at $55.51, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas RNAM's P/E ratio is -17.39. In terms of profitability, XENE's ROE is -0.49%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, XENE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check RNAM's competition here
XENE vs ARWR Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, XENE is priced at $55.51, while ARWR trades at $78.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ARWR's P/E ratio is -34.82. In terms of profitability, XENE's ROE is -0.49%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, XENE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ARWR's competition here
XENE vs BMRN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, XENE is priced at $55.51, while BMRN trades at $53.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas BMRN's P/E ratio is 38.04. In terms of profitability, XENE's ROE is -0.49%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, XENE is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check BMRN's competition here
XENE vs RXDX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, XENE is priced at $55.51, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas RXDX's P/E ratio is -56.47. In terms of profitability, XENE's ROE is -0.49%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, XENE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check RXDX's competition here
XENE vs CYTK Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CYTK has a market cap of 9.3B. Regarding current trading prices, XENE is priced at $55.51, while CYTK trades at $76.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CYTK's P/E ratio is -10.92. In terms of profitability, XENE's ROE is -0.49%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, XENE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check CYTK's competition here
XENE vs KRYS Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, XENE is priced at $55.51, while KRYS trades at $316.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas KRYS's P/E ratio is 41.49. In terms of profitability, XENE's ROE is -0.49%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, XENE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check KRYS's competition here
XENE vs IMGN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, XENE is priced at $55.51, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas IMGN's P/E ratio is -111.55. In terms of profitability, XENE's ROE is -0.49%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, XENE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check IMGN's competition here
XENE vs IBRX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, XENE is priced at $55.51, while IBRX trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas IBRX's P/E ratio is -10.02. In terms of profitability, XENE's ROE is -0.49%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, XENE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check IBRX's competition here
XENE vs HALO Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, XENE is priced at $55.51, while HALO trades at $68.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas HALO's P/E ratio is 24.89. In terms of profitability, XENE's ROE is -0.49%, compared to HALO's ROE of +1.26%. Regarding short-term risk, XENE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check HALO's competition here
XENE vs BPMC Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, XENE is priced at $55.51, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas BPMC's P/E ratio is -51.58. In terms of profitability, XENE's ROE is -0.49%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, XENE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check BPMC's competition here
XENE vs CERE Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, XENE is priced at $55.51, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CERE's P/E ratio is -16.47. In terms of profitability, XENE's ROE is -0.49%, compared to CERE's ROE of -0.72%. Regarding short-term risk, XENE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check CERE's competition here
XENE vs ABVX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, XENE is priced at $55.51, while ABVX trades at $121.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ABVX's P/E ratio is -21.41. In terms of profitability, XENE's ROE is -0.49%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, XENE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ABVX's competition here
XENE vs PCVX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, XENE is priced at $55.51, while PCVX trades at $54.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas PCVX's P/E ratio is -7.84. In terms of profitability, XENE's ROE is -0.49%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, XENE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check PCVX's competition here
XENE vs NUVL Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, XENE is priced at $55.51, while NUVL trades at $103.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas NUVL's P/E ratio is -16.92. In terms of profitability, XENE's ROE is -0.49%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, XENE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check NUVL's competition here
XENE vs MTSR Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, XENE is priced at $55.51, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas MTSR's P/E ratio is -23.58. In terms of profitability, XENE's ROE is -0.49%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, XENE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check MTSR's competition here
XENE vs TECH Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, TECH has a market cap of 7.4B. Regarding current trading prices, XENE is priced at $55.51, while TECH trades at $44.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas TECH's P/E ratio is 67.74. In terms of profitability, XENE's ROE is -0.49%, compared to TECH's ROE of +0.05%. Regarding short-term risk, XENE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check TECH's competition here
XENE vs PRAX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, XENE is priced at $55.51, while PRAX trades at $340.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas PRAX's P/E ratio is -25.65. In terms of profitability, XENE's ROE is -0.49%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, XENE is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check PRAX's competition here
XENE vs KYMR Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, XENE is priced at $55.51, while KYMR trades at $85.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas KYMR's P/E ratio is -23.34. In terms of profitability, XENE's ROE is -0.49%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, XENE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check KYMR's competition here
XENE vs MRUS Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, XENE is priced at $55.51, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas MRUS's P/E ratio is -17.05. In terms of profitability, XENE's ROE is -0.49%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, XENE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check MRUS's competition here
XENE vs ACLX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, XENE is priced at $55.51, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ACLX's P/E ratio is -28.27. In terms of profitability, XENE's ROE is -0.49%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, XENE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check ACLX's competition here
XENE vs RETA Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, XENE is priced at $55.51, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas RETA's P/E ratio is -66.29. In terms of profitability, XENE's ROE is -0.49%, compared to RETA's ROE of +0.47%. Regarding short-term risk, XENE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check RETA's competition here
XENE vs TGTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, TGTX has a market cap of 6.5B. Regarding current trading prices, XENE is priced at $55.51, while TGTX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas TGTX's P/E ratio is 14.87. In terms of profitability, XENE's ROE is -0.49%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, XENE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check TGTX's competition here
XENE vs PTGX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, XENE is priced at $55.51, while PTGX trades at $102.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas PTGX's P/E ratio is -55.22. In terms of profitability, XENE's ROE is -0.49%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, XENE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check PTGX's competition here
XENE vs ALKS Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ALKS has a market cap of 6.4B. Regarding current trading prices, XENE is priced at $55.51, while ALKS trades at $39.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ALKS's P/E ratio is 42.54. In terms of profitability, XENE's ROE is -0.49%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, XENE is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ALKS's competition here
XENE vs RYTM Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, RYTM has a market cap of 6.3B. Regarding current trading prices, XENE is priced at $55.51, while RYTM trades at $95.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas RYTM's P/E ratio is -29.17. In terms of profitability, XENE's ROE is -0.49%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, XENE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check RYTM's competition here
XENE vs PTCT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, PTCT has a market cap of 6.2B. Regarding current trading prices, XENE is priced at $55.51, while PTCT trades at $73.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas PTCT's P/E ratio is -29.54. In terms of profitability, XENE's ROE is -0.49%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, XENE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check PTCT's competition here
XENE vs BLTE Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, XENE is priced at $55.51, while BLTE trades at $154.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas BLTE's P/E ratio is -67.63. In terms of profitability, XENE's ROE is -0.49%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, XENE is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check BLTE's competition here
XENE vs CNTA Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, XENE is priced at $55.51, while CNTA trades at $39.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CNTA's P/E ratio is -22.25. In terms of profitability, XENE's ROE is -0.49%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, XENE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check CNTA's competition here
XENE vs CGON Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, XENE is priced at $55.51, while CGON trades at $73.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CGON's P/E ratio is -30.80. In terms of profitability, XENE's ROE is -0.49%, compared to CGON's ROE of -0.23%. Regarding short-term risk, XENE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check CGON's competition here
XENE vs CELC Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, XENE is priced at $55.51, while CELC trades at $122.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CELC's P/E ratio is -32.90. In terms of profitability, XENE's ROE is -0.49%, compared to CELC's ROE of -2.03%. Regarding short-term risk, XENE is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check CELC's competition here
XENE vs COGT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, XENE is priced at $55.51, while COGT trades at $34.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas COGT's P/E ratio is -15.91. In terms of profitability, XENE's ROE is -0.49%, compared to COGT's ROE of -0.83%. Regarding short-term risk, XENE is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check COGT's competition here
XENE vs SRRK Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, XENE is priced at $55.51, while SRRK trades at $49.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas SRRK's P/E ratio is -14.26. In terms of profitability, XENE's ROE is -0.49%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, XENE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check SRRK's competition here
XENE vs IMVT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, IMVT has a market cap of 5.8B. Regarding current trading prices, XENE is priced at $55.51, while IMVT trades at $29.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas IMVT's P/E ratio is -10.73. In terms of profitability, XENE's ROE is -0.49%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, XENE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check IMVT's competition here
XENE vs CDTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, XENE is priced at $55.51, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CDTX's P/E ratio is -19.77. In terms of profitability, XENE's ROE is -0.49%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, XENE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check CDTX's competition here
XENE vs ABCM Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, XENE is priced at $55.51, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, XENE's ROE is -0.49%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, XENE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check ABCM's competition here
XENE vs ISEE Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, XENE is priced at $55.51, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ISEE's P/E ratio is -22.44. In terms of profitability, XENE's ROE is -0.49%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, XENE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check ISEE's competition here
XENE vs CORT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, XENE is priced at $55.51, while CORT trades at $57.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CORT's P/E ratio is 146.17. In terms of profitability, XENE's ROE is -0.49%, compared to CORT's ROE of +0.08%. Regarding short-term risk, XENE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check CORT's competition here
XENE vs MIRM Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, XENE is priced at $55.51, while MIRM trades at $111.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas MIRM's P/E ratio is -7.86. In terms of profitability, XENE's ROE is -0.49%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, XENE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check MIRM's competition here
XENE vs APLS Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, XENE is priced at $55.51, while APLS trades at $41.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas APLS's P/E ratio is 38.37. In terms of profitability, XENE's ROE is -0.49%, compared to APLS's ROE of +0.40%. Regarding short-term risk, XENE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check APLS's competition here
XENE vs LEGN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, XENE is priced at $55.51, while LEGN trades at $28.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas LEGN's P/E ratio is -20.48. In terms of profitability, XENE's ROE is -0.49%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, XENE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check LEGN's competition here
XENE vs FBIOX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, XENE is priced at $55.51, while FBIOX trades at $25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas FBIOX's P/E ratio is N/A. In terms of profitability, XENE's ROE is -0.49%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, XENE is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check FBIOX's competition here
XENE vs APGE Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, XENE is priced at $55.51, while APGE trades at $83.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas APGE's P/E ratio is -19.15. In terms of profitability, XENE's ROE is -0.49%, compared to APGE's ROE of -0.24%. Regarding short-term risk, XENE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check APGE's competition here
XENE vs CRSP Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, XENE is priced at $55.51, while CRSP trades at $53.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CRSP's P/E ratio is -8.56. In terms of profitability, XENE's ROE is -0.49%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, XENE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check CRSP's competition here
XENE vs LQDA Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, LQDA has a market cap of 5B. Regarding current trading prices, XENE is priced at $55.51, while LQDA trades at $56.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas LQDA's P/E ratio is 332.94. In terms of profitability, XENE's ROE is -0.49%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, XENE is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check LQDA's competition here
XENE vs TERN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, XENE is priced at $55.51, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas TERN's P/E ratio is -51.41. In terms of profitability, XENE's ROE is -0.49%, compared to TERN's ROE of -0.20%. Regarding short-term risk, XENE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check TERN's competition here
XENE vs CAI Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, XENE is priced at $55.51, while CAI trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CAI's P/E ratio is -6.07. In terms of profitability, XENE's ROE is -0.49%, compared to CAI's ROE of +0.06%. Regarding short-term risk, XENE is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check CAI's competition here
XENE vs FOLD Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, XENE is priced at $55.51, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas FOLD's P/E ratio is -161.00. In terms of profitability, XENE's ROE is -0.49%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, XENE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check FOLD's competition here
XENE vs NAMS Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, NAMS has a market cap of 4.5B. Regarding current trading prices, XENE is priced at $55.51, while NAMS trades at $37.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas NAMS's P/E ratio is -21.85. In terms of profitability, XENE's ROE is -0.49%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, XENE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check NAMS's competition here
XENE vs SYRE Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, XENE is priced at $55.51, while SYRE trades at $77.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas SYRE's P/E ratio is -35.40. In terms of profitability, XENE's ROE is -0.49%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, XENE is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check SYRE's competition here
XENE vs AKRO Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, XENE is priced at $55.51, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas AKRO's P/E ratio is -14.57. In terms of profitability, XENE's ROE is -0.49%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, XENE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check AKRO's competition here
XENE vs KNSA Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, KNSA has a market cap of 4.5B. Regarding current trading prices, XENE is priced at $55.51, while KNSA trades at $59.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas KNSA's P/E ratio is 65.36. In terms of profitability, XENE's ROE is -0.49%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, XENE is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check KNSA's competition here
XENE vs ALPN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, XENE is priced at $55.51, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ALPN's P/E ratio is -101.52. In terms of profitability, XENE's ROE is -0.49%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, XENE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check ALPN's competition here
XENE vs LGND Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, XENE is priced at $55.51, while LGND trades at $223.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas LGND's P/E ratio is 28.98. In terms of profitability, XENE's ROE is -0.49%, compared to LGND's ROE of +0.16%. Regarding short-term risk, XENE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check LGND's competition here
XENE vs MANE Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, XENE is priced at $55.51, while MANE trades at $107.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas MANE's P/E ratio is -43.66. In terms of profitability, XENE's ROE is -0.49%, compared to MANE's ROE of -0.76%. Regarding short-term risk, XENE is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check MANE's competition here
XENE vs OPT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, XENE is priced at $55.51, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas OPT's P/E ratio is -1.52. In terms of profitability, XENE's ROE is -0.49%, compared to OPT's ROE of +0.88%. Regarding short-term risk, XENE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check OPT's competition here
XENE vs MRTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, XENE is priced at $55.51, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas MRTX's P/E ratio is -4.82. In terms of profitability, XENE's ROE is -0.49%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, XENE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check MRTX's competition here
XENE vs TVTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, XENE is priced at $55.51, while TVTX trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas TVTX's P/E ratio is -85.68. In terms of profitability, XENE's ROE is -0.49%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, XENE is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check TVTX's competition here
XENE vs CRNX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, XENE is priced at $55.51, while CRNX trades at $37.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CRNX's P/E ratio is -7.18. In terms of profitability, XENE's ROE is -0.49%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, XENE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check CRNX's competition here
XENE vs CPRX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, XENE is priced at $55.51, while CPRX trades at $31.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CPRX's P/E ratio is 18.00. In terms of profitability, XENE's ROE is -0.49%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, XENE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check CPRX's competition here
XENE vs RYZB Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, XENE is priced at $55.51, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas RYZB's P/E ratio is -57.86. In terms of profitability, XENE's ROE is -0.49%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, XENE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check RYZB's competition here
XENE vs CBAY Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, XENE is priced at $55.51, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas CBAY's P/E ratio is -32.81. In terms of profitability, XENE's ROE is -0.49%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, XENE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check CBAY's competition here
XENE vs ACAD Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, XENE is priced at $55.51, while ACAD trades at $21.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ACAD's P/E ratio is 9.83. In terms of profitability, XENE's ROE is -0.49%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, XENE is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ACAD's competition here
XENE vs EWTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, XENE is priced at $55.51, while EWTX trades at $33.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas EWTX's P/E ratio is -20.49. In terms of profitability, XENE's ROE is -0.49%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, XENE is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check EWTX's competition here
XENE vs VKTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, XENE is priced at $55.51, while VKTX trades at $31.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas VKTX's P/E ratio is -7.55. In terms of profitability, XENE's ROE is -0.49%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, XENE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check VKTX's competition here
XENE vs DNTH Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, XENE is priced at $55.51, while DNTH trades at $84.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas DNTH's P/E ratio is -20.37. In terms of profitability, XENE's ROE is -0.49%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, XENE is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check DNTH's competition here
XENE vs SWTX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, XENE is priced at $55.51, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas SWTX's P/E ratio is -13.78. In terms of profitability, XENE's ROE is -0.49%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, XENE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check SWTX's competition here
XENE vs TLX Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, XENE is priced at $55.51, while TLX trades at $10.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas TLX's P/E ratio is -519.50. In terms of profitability, XENE's ROE is -0.49%, compared to TLX's ROE of -0.02%. Regarding short-term risk, XENE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for XENE.Check TLX's competition here
XENE vs BEAM Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, XENE is priced at $55.51, while BEAM trades at $32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas BEAM's P/E ratio is -64.45. In terms of profitability, XENE's ROE is -0.49%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, XENE is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check BEAM's competition here
XENE vs ERAS Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, XENE is priced at $55.51, while ERAS trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas ERAS's P/E ratio is -11.16. In terms of profitability, XENE's ROE is -0.49%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, XENE is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check ERAS's competition here
XENE vs VCYT Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, XENE is priced at $55.51, while VCYT trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas VCYT's P/E ratio is 36.63. In terms of profitability, XENE's ROE is -0.49%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, XENE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check VCYT's competition here
XENE vs NAMSW Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, NAMSW has a market cap of 3.1B. Regarding current trading prices, XENE is priced at $55.51, while NAMSW trades at $27.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas NAMSW's P/E ratio is N/A. In terms of profitability, XENE's ROE is -0.49%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, XENE is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check NAMSW's competition here
XENE vs DNLI Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, XENE is priced at $55.51, while DNLI trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas DNLI's P/E ratio is -6.76. In terms of profitability, XENE's ROE is -0.49%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, XENE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check DNLI's competition here
XENE vs DYN Comparison May 2026
XENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XENE stands at 4.3B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, XENE is priced at $55.51, while DYN trades at $18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XENE currently has a P/E ratio of -11.70, whereas DYN's P/E ratio is -5.83. In terms of profitability, XENE's ROE is -0.49%, compared to DYN's ROE of -0.58%. Regarding short-term risk, XENE is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for XENE.Check DYN's competition here